Shreya Agarwal: We Describe Patients With PLG Mutations Who Experienced Recurrent TMA
Shreya Agarwal, Assistant Professor of Pediatric Hematology at UCSF Benioff Children’s Hospitals, reposted from RPTH Journal on LinkedIn:
”Grateful to RPTH for highlighting our recent study on Plasminogen (PLG) mutation- associated thrombotic microangiopathy (TMA).
In this work, we describe patients with PLG mutations who experienced recurrent TMA despite complement blockade therapy, and raises suspicion if there is an alternate disease pathway worth exploring.
We are now hoping to assess the feasibility of a multicenter study to better understand PLG mutations-associated TMA.
If you’ve cared for patients with plasminogen mutations and TMA, we’d be grateful if you could take a few minutes to complete our short survey.
Thank you to my amazing coauthors Nicola Pozzi, Senthil Sukumar, Camila Masias MD, Anuja Java and Spero Cataland for their collaboration on this project!”
Quoting RPTH Journal‘s post:
”Not all thrombotic microangiopathies (TMAs) behave the same, and they don’t all respond to complement blockade.
In a new study, Shreya Agarwal, MD and team describe a subset of patients with plasminogen (PLG) mutations who experienced recurrent TMA despite standard therapy.
Their response to anticoagulation hints at an alternative disease pathway worth exploring.
Coauthors: Nicola Pozzi; Senthil Sukumar, Camila Masias MD, Spero Cataland’‘
Read the full article in RPTH.
Article: Plasminogen mutation–associated thrombotic microangiopathy and role of anticoagulation: a single institution case series
Authors: Shreya Agarwal, Nicola Pozzi, Senthil Sukumar, Camila Masias, Anuja Java, Spero Cataland

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 15:02Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:50Steve Tuplin on Roche’s Mission at ASH25
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 5, 2025, 03:46Sreeni Sivan Pillai: Preventing Thrombophlebitis and Upper Limb DVT in PICC Lines
